Lisinopril is an ACE inhibitor widely used to treat hypertension and heart failure. By inhibiting the conversion of angiotensin I to angiotensin II, it reduces peripheral vascular resistance and blood pressure.
Also known as: Zestril, Prinivil
ACE inhibitor + thiazide: potential for excessive hypotension.
The combination may cause symptomatic hypotension. Start ACEI at low dose and adjust according to hemodynamic response.
DailyMed/FDA (NIH/NLM) — approved Lisinopril label: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e6898cf8-34c8-44d5-8a86-fbe3be847b16
ACE inhibitor + loop diuretic: potential for excessive hypotension.
The combination may cause symptomatic hypotension, especially with the first ACE inhibitor dose. Start ACEI at low dose and adjust according to response.
DailyMed/FDA (NIH/NLM) — approved Lisinopril label: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e6898cf8-34c8-44d5-8a86-fbe3be847b16
ACE inhibitor + spironolactone: serious risk of hyperkalaemia.
Both reduce renal potassium excretion. The combination can cause severe and potentially fatal hyperkalaemia. Monitor K+ and renal function closely.
DailyMed/FDA (NIH/NLM) — approved Lisinopril label: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e6898cf8-34c8-44d5-8a86-fbe3be847b16
No documented food or drink interactions.
May worsen renal impairment. Reduce dose or discontinue if creatinine >3x normal.
Monitor GFR and creatinine. Adjust or discontinue according to renal function.
DailyMed/FDA (NIH/NLM) — approved Lisinopril label: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e6898cf8-34c8-44d5-8a86-fbe3be847b16
CONTRAINDICATED in pregnancy. Teratogenic effects: renal malformations, pulmonary hypoplasia, neonatal hypotension.
CONTRAINDICATED in all trimesters.
Unknown if excreted in breast milk. Prefer alternatives.
Discontinue before conception. Do not use during pregnancy or breastfeeding.
DailyMed/FDA (NIH/NLM) — approved Lisinopril label: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e6898cf8-34c8-44d5-8a86-fbe3be847b16
Clinical and educational support tool. The information does not replace a medical prescription or the opinion of a qualified healthcare professional.
Inhibits the angiotensin-converting enzyme (ACE), blocking conversion of angiotensin I to angiotensin II and degrading bradykinin.
ACE blockade results in reduced angiotensin II (vasoconstriction) and bradykinin accumulation (vasodilation). Dual antihypertensive effect.
Oral bioavailability: ~25%. Food does not significantly affect absorption. Tmax: 7 hours.
Not metabolised — excreted unchanged by the renal route. Does not undergo significant hepatic metabolism. Not a prodrug.
12 hours. Elimination: 100% renal (unchanged). Adjust dose in renal impairment.
Medicines from the same therapeutic group (ATC classification) or the same pharmacological class.
